Table 4.
Major reports on p21WAF1 expression and survival of patients with CRCs
| Source | Study group | Stage of CRC and type of treatment | Results |
|---|---|---|---|
| Cheng J.D., et al. [10] | n = 39 | Metastatic CRC 5FU CHTH | 5FU responders had greater p21 expression |
| Ropponen K.M, et al. [11] | n = 162 | 0–D incl. 62–B majority: surgery only; 22–CHTH | Better OS and RFS for patients with p21+ tumors; p21: independent prognostic parameter for OS and RFS (MA) |
| Viale G., et al. [12] | n = 191 | I–IV CHTH? | ↓p21 → poor OS and DFS (UA) |
| Bukholm I.K., et al. [13] | n = 61 | B–D CHTH? | Low p21 → increased risk of metastases and death |
| Zirbes T.K., et al. [14] | n = 294 | I–IV incl. 90–II. surgery CHTH? | Better OS for patients with p21+ tumors; p21 independent prognostic parameter (MA) |
| Holland T.A., et al. [15] | n = 126 | A–D RCHTH? | Better OS for patients with high p21 expression |
| Pasz-Walczak G., et al. [16] | n = 122 | I–IV CHTH? | Better OS for patients with p21+ tumors (UA) |
| Watanabe T., et al. [20] | n = 460 | II (B)–105 III (C)–355, 5FU CHTH | No association of p21 expression with survival in all and in stage B tumors |
| Hoss A., et al. [21] | n = 100 | T2–3, N0 rectum, surgery only | No association of p21 expression with survival |
| Schwandner O., et al. [17] | n = 160 | I–III rectum, surgery, n = 69 surgery + CHTH + RT, n = 91 | Better RFS but not OS for patients with p21+ tumors; p21 independent prognostic parameter for RFS but not OS (MA) |
| Rau B., et al. [22] | n = 66 | T3–4, N0–2, M0–1 rectum, RCHTH | No prognostic significance of pretreatment p21 expression. Post-treatment increase of p21: shorter DFS |
| Prall F., et al. [18] | n = 184 | I–IV incl. 55-III, III: n = 32 -5FU, n = 23-5FU + RT | Better OS for patients with p21 + tumors (MA) |
| Mitomi H., et al. [19] | n = 211 | B–D incl. 83-B CHTH for C–D | Better OS for patients with high p21 expression; p21 independent prognostic parameter (MA) |
| Ioachim E., et al. [23] | n = 97 | Dukes B, C, surgery, CHTH? | No association of p21 expression with OS and DFS |
| Noske A., et al. [24] | n = 116 | II–III RCHTH | Better RFS and OS for patients with p21- tumors |
↓ down regulation, UA univariate analysis, MA multivariate analysis, OS overall survival, DFS disease-free survival, RFS relapse-free survival, RT radiotherapy, CHTH chemotherapy, RCHTH radiochemotherapy, ? not known